PAD isozyme-specific inhibitor treatment in the two GBM cell lines reflects to some extent the finding that PAD2 and PAD4 are higher expressed in LN18 cells compared to PAD3, while PAD3 is higher expressed in LN229 cells compared to PAD2 and PAD4 [9] (Supplementary Figure S1A). The gene discussed is PADI3; the disease is glioblastoma.